First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus

Doo Ryeon Chung; Jin Yang Baek; Hyun Ah Kim; Min Hee Lim; So Hyun Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song

doi:10.1128/JCM.00590-12

First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus

J Clin Microbiol. 2012 Jul;50(7):2513-4. doi: 10.1128/JCM.00590-12. Epub 2012 May 2.

Authors

Doo Ryeon Chung¹, Jin Yang Baek, Hyun Ah Kim, Min Hee Lim, So Hyun Kim, Kwan Soo Ko, Cheol-In Kang, Kyong Ran Peck, Nam Yong Lee, Jae-Hoon Song

Affiliation

¹ Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. drchung@skku.edu

Abstract

Vancomycin-intermediate resistance has not been previously reported among sequence type 72 (ST72) methicillin-resistant Staphylococcus aureus (MRSA) isolates of SCCmec type IV (ST72-MRSA-IV), which are distinctive community genotype strains in Korea. We report the first case of vancomycin treatment failure due to development of vancomycin-intermediate resistance in infection caused by an ST72-MRSA-IV isolate.

Publication types

Case Reports

MeSH terms

Aged
Anti-Bacterial Agents / pharmacology*
Anti-Bacterial Agents / therapeutic use
Genotype
Humans
Korea
Male
Methicillin-Resistant Staphylococcus aureus / drug effects*
Methicillin-Resistant Staphylococcus aureus / genetics
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
Staphylococcal Infections / drug therapy
Staphylococcal Infections / microbiology*
Treatment Failure
Vancomycin / pharmacology*
Vancomycin / therapeutic use
Vancomycin Resistance*

Substances

Anti-Bacterial Agents
Vancomycin